Recon: FDA advisors vote 6-4 against Amylyx ALS drug; Vertex’s non-opioid pain reliever shows success in mid-stage studies
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy